

CELL THERAPEUTICS INC  
Form 8-K  
October 20, 2003

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2003

## CELL THERAPEUTICS, INC.

---

(Exact name of Registrant as specified in its charter)

Washington

(State or other jurisdiction of  
incorporation or organization)

0-28386

(Commission File Number)

91-1533912

(I.R.S. Employer  
Identification Number)

**501 Elliott Avenue West, Suite 400**

**Seattle, WA 98119**

---

**(Address of principal executive offices) (Zip Code)**

**(206) 282-7100**

---

**(Registrant's telephone number, including area code)**

**Not Applicable**

---

**(Former name or former address, if changed since last report.)**

---

**Item 5. Other Events.**

On October 20, 2003, Cell Therapeutics, Inc. issued a press release announcing that it had implemented a study amendment in its STELLAR 4 trial. The full text of the press release is set forth in Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits.

<u>Exhibit</u>	<u>Description</u>
99.1	Press release of Cell Therapeutics, Inc. issued on October 20, 2003.



**Index to Exhibits**

<b>Exhibit</b>	<b>Description</b>
99.1	Press release of Cell Therapeutics, Inc. issued on October 20, 2003.